Notícias e Atividades da Apogee Therapeutics

Apogee Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Apogee Therapeutics é uma empresa listada sob o símbolo APGE (US).

Veja o organograma con seus 29 executivos principais

Biografias mais buscadas da Apogee Therapeutics

• Michael Henderson, Chief Executive Officer and Director
• BJ Jones, Director
• Andrew Gottesdiener, Director

Recentes movimentos de executivos em Apogee Therapeutics

• Jeff Hartness, ingressou na Companhia como Chief Commercial Officer  (Notícia publicada em 10 de setembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Apogee Therapeutics.

Apogee Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Apogee Therapeutics

• Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results | Apogee Therapeutics, Inc.
• News | Apogee Therapeutics, Inc.
• Apogee Therapeutics to Participate in Upcoming November Investor Conferences | Apogee Therapeutics, Inc.
• News | Apogee Therapeutics, Inc.
• Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day | Apogee Therapeutics, Inc.
• Publications | Apogee Therapeutics, Inc.
• Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress | Apogee Therapeutics, Inc.
• Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results | Apogee Therapeutics, Inc.
• Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board | Apogee Therapeutics, Inc.
• Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases | Apogee Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Apogee Therapeutics

• Apogee Therapeutics na Wikipedia, Google News e Yahoo Finance
• Apogee Therapeutics na LinkedIn, Twitter e YouTube